A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants

Phase 2

Completed

• Conditions: Coronary Artery Disease; Healthy Participants
• Interventions: Drug: Ticagrelor; Drug: BMS-986141; Drug: Aspirin

• Registration Number: NCT05093790
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The purpose of this study is to assess the effectiveness, safety and tolerability of BMS-986141 added on to aspirin or ticagrelor or the combination on thrombus formation in both healthy participants and participants with stable coronary artery disease.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-10-14
• Study First Submitted QC: 2021-10-14
• Study First Posted: 2021-10-26
• Study Start: 2022-03-25
• Primary Completion: 2022-11-14
• Study Completion: 2022-11-14
• Status Verified: 2023-11
• Results First Submitted: 2023-11-13
• Results First Submitted QC: 2023-11-13
• Last Update Submitted: 2023-11-13
• Results First Posted: 2023-12-05
• Last Update Posted: 2023-12-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

• Male or female between 18 to 75 years of age, inclusive, and body mass index (weight kg/m2) between 18 and 35 kg/m2 (inclusive), and body weight 50 kg and 120 kg (inclusive)
• Judged to be generally in good health based on medical history, physical examination, ECGs, vital signs and laboratory tests
• Signed an informed consent document indicating they understand the purpose of and procedures required for the experiment and are willing to participate in the experiment
• Willing/able to adhere to the visit schedule
• For treatment arms groups with stable CAD participants (not for healthy volunteers without CAD) one or more of: Prior angiographically proven CAD (>50% stenosis of proximal coronary artery), prior coronary revascularization (PCI or CABG), prior myocardial infarction (MI)

Read More

Exclusion Criteria

• Participants who meet any of the following criteria will be excluded from participating in the experiment: Allergies or intolerance of aspirin, ticagrelor and BMS-986141, requirement for dual antiplatelet therapy, requirement for anticoagulant therapy
• Acute Coronary syndrome or coronary revascularization within 3 months
• Coagulation disorders (including any abnormal bleeding or blood dyscrasias), anemia, renal or hepatic insufficiency or any others illness that the investigator considers should exclude the participants/patients of that could interfere with the interpretation to the results
• Acute illness, including a common cold, within 7 days prior to visit or other significant acute or chronic medical illness
• Major or traumatic surgery within 12 weeks of screening
• History of, a reason to believe that, a blood donor subject has a history of drug or alcohol abuse within the past 5 years or has not abstained from alcohol for at least 24 hours prior to visit
• Positive serum or urine pregnancy test
• Not anatomically suitable for or unwilling to undergo venipunctures
• Participation in a study of an investigational medicinal product within the last 4 weeks
• Any condition that, in the opinion of the investigator, would compromise the wellbeing of the blood donor subject or the experiment or prevent the blood donor subject from meeting or performing experiment requirements

Other protocol-defined inclusion/exclusion criteria apply

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment Arm 1: Ticagrelor + BMS-986141	BMS-986141	-
Treatment Arm 3: Ticagrelor + Aspirin + BMS-986141	BMS-986141	-
Treatment Arm 3: Ticagrelor + Aspirin + BMS-986141	Aspirin	-
Treatment Arm 4: BMS-986141	BMS-986141	-
Treatment Arm 1: Ticagrelor + BMS-986141	Ticagrelor	-
Treatment Arm 3: Ticagrelor + Aspirin + BMS-986141	Ticagrelor	-
Treatment Arm 2: Aspirin + BMS-986141	Aspirin	-
Treatment Arm 2: Aspirin + BMS-986141	BMS-986141	-

Primary Outcome Measures

Name	Time	Method
Percent Change From Baseline in Thrombus Area	Baseline, Day 1 hour 2, Day 2 hour 24	The change from baseline in thrombus area post-treatment with BMS-986141 versus pretreatment. Baseline is defined as the last non-missing result (including repeated and unscheduled assessments) with a collection date-time less than the datetime of study medication.

Secondary Outcome Measures

Name	Time	Method
Number of Participants Experiencing Abnormal Vital Signs	Vital signs will be collected at check-in and prior to and after each chamber assessment on Days 1 and 2	The number of participants with abnormal vital sign values. The criteria used for classifying vital sign results as markedly abnormal is listed below. Baseline is defined as the last non-missing result with a collection date-time less than the date-time of the first dose of study medication. For Treatment Arms 1, 2, and 3, a baseline chamber run was performed approximately 2 hours after background therapy (ticagrelor, aspirin, or ticagrelor + aspirin) and prior to BMS-986141 administration. A second chamber run was performed 2 hours following oral administration of BMS-986141. For Treatment Arm 4, a baseline chamber run was performed prior to BMS-986141 administration. A second chamber run was performed 2 hours following oral administration of BMS-986141. Participants received background therapy before the final chamber run, and the final chamber run was performed on Day 2, approximately 24 hours after BMS-986141 dosing.
Number of Participants Experiencing Abnormal Electrocardiogram (ECG) Values	Electrocardiograms were collected at check-in, and 2 and 24 hours after dosing	The number of participants with abnormal electrocardiogram values. The criteria used for classifying electrocardiogram results as markedly abnormal is listed below. The 2-hour and 24-hour ECGs should are performed prior to the Badimon Chamber run. Baseline is defined as the last non-missing result with a collection date-time less than the date-time of the first dose of study medication.
Number of Participants Experiencing Clinical Lab Abnormalities	From baseline up to 24 hours post dose	The number of participants with abnormal clinical laboratory results. The criteria used for classifying laboratory test results as markedly abnormal is listed below.
Number of Participants Experiencing Adverse Events (AEs)	From first dose up to 8 days post last dose	An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Trial Locations

Locations (1)

Local Institution - 0001; 🇬🇧 Edinburgh, United Kingdom